ID   GR-M
AC   CVCL_2451
SY   GRM
DR   CLO; CLO_0003564
DR   EFO; EFO_0006577
DR   CLDB; cl1513
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03472907
DR   BioSample; SAMN10988055
DR   cancercelllines; CVCL_2451
DR   Cell_Model_Passport; SIDM00468
DR   Cosmic; 2163785
DR   DepMap; ACH-001072
DR   ECACC; 95032301
DR   EGA; EGAS00001000610
DR   ESTDAB; ESTDAB-036
DR   IARC_TP53; 21349
DR   PharmacoDB; GRM_412_2019
DR   Progenetix; CVCL_2451
DR   Wikidata; Q54871656
RX   PubMed=7780963;
RX   PubMed=15592718;
RX   PubMed=23851445;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a PSN1 derivative (PubMed=25877200). Originally thought to originate from the chest of a 36 year old male melanoma patient with skin metastases.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00538.
CC   Population: Japanese.
CC   HLA typing: A*24:02,24:02; B*52:01:01,52:01:01; C*12:02,12:02; DPB1*09:01; DQB1*06:02,06:01:01; DRB1*15:01 (PubMed=15592718).
CC   HLA typing: A*24:02,24:02; B*52:01,52:01; C*12:02,12:02 (PubMed=26589293).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Gln (c.394A>C); ClinVar=VCV000376628; Zygosity=Unspecified (PubMed=23851445; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=83.55%; East Asian, South=15.04%; South Asian=1.41%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: ESTDAB; ESTDAB-036; probable.
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
ST   Source(s): PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 10
ST   D16S539: 10,11
ST   D18S51: 21
ST   D21S11: 29,30
ST   D3S1358: 15
ST   D5S818: 11,13
ST   D7S820: 10
ST   D8S1179: 10,14
ST   FGA: 23
ST   Penta D: 9,12
ST   Penta E: 14,15
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C8294; Pancreatic adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1644 ! PSN1
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 30
//
RX   PubMed=7780963;
RA   Easty D.J., Guthrie B.A., Maung K., Farr C.J., Lindberg R.A.,
RA   Toso R.J., Herlyn M., Bennett D.C.;
RT   "Protein B61 as a new growth factor: expression of B61 and
RT   up-regulation of its receptor epithelial cell kinase during melanoma
RT   progression.";
RL   Cancer Res. 55:2528-2532(1995).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//